Prostate-specific antigen, clinical use and staging: An overview

British Journal of Urology

Volumn 79, Issue SUPPL. 1, 1997, Pages 53-60

  Stenman, U H ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; PROTEINASE INHIBITOR; TUMOR MARKER;

BLOOD LEVEL; CANCER SCREENING; CANCER STAGING; COMPLEX FORMATION; CONFERENCE PAPER; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR VOLUME;

ADULT; AGED; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROTEASE INHIBITORS; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 0031403862     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410x.1997.tb00802.x     Document Type: Article

References (53)

1. Wang MC, Valenzuela LA, Murphy GP. Chu TM. Purification of a human prostate-specific antigen. Invest Ural 1979: 17: 159-63
2. Frazier HA, Humphrey PA, Burchette JL, Paulson DF. Immunoreactive prostatic specific antigen in male periurethral glands. J Urol 1992; 147: 246-8
3. Levesque M, Hu H, D'Costa M. Diamandis EP. Prostatespecific antigen expression by various tumors. J Clin Lab Anal 1995; 9: 123-8
4. Abrahamsson PA, Lilja H, Falkmer S, Wadstrom LB. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 1988; 12: 39-46
5. 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594-8
6. Stamey TA, Yang N, Hay AR, McNeal JE. Freiha FS. Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987: 317: 909-16
7. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 1732-6
8. Catalona WJ, Smith DS, Ratliff TL. Basier JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54
9. Labrie F, Candas B, Cusan L et al. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology 1996; 47: 212-17
10. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60
11. Babaian RJ, Pritsche HA, Evans RB. Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990; 4: 135-7
12. Oesterling JE, Jacobsen SJ, KLee GG et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995: 154: 1090-5
13. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 1990; 194: 755-63
14. Stenman U-H. Leinonen J, Zhang W-M. Problems of PSA determinations. Eur J Clin Chem Clin Biochem 1996; 34: 735-40
15. Stenman U-H. Leinonen J, Alfthan H. Rannikko S. Tuhkanen K, Alfthan O. A complex between prostatespecific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6
16. Lilja H, Björk T, Abrahamsson P-A et al. Improved separation between normals, benign prostatic hyperplasia (BPH) and carcinoma of the prostate (CAP) by measuring free (F), complexed (C) and total concentrations (T) of prostate specific antigen (PSA). J Urol 1994: 151: 400A
17. Stanley TA, Chen ZX, Prestigiacomo A. Serum prostate specific antigen binding alpha 1-antichymotrypsin: influence of cancer volume, location and therapeutic selection of resistant clones. J Urol 1994: 152: 1510-14
18. Catalona W, Smith D. Wolfert R, Wang T, Rittenhous H, Ratliff T. Increased specificity of PSA screening through measurement of percentage free PSA in serum. J Urol 1995; 153: 312A. Abstr 336
19. Zhou AM, Tewari PC, Bluestein BI, Caldwell GW, Larsen FL. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 1993; 39: 2483-91
20. Espana F, Sanchez CJ, Estelles A, Gilabert J, Griffin JH, Heeb MJ. Quantitative immunoassay for complexes of prostate-specific antigen with alpha2-macroglobulin. Clin Chem 1996; 42: 545-50
21. Leinonen J, Zhang W-M, Stenman U-H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155: 1099-103
22. 1-protease inhibitor in vitro. J Urol 1996; 155: 626A (Abstr)
23. Zhang W-M, Leinonen J, Kalkkinen N, Dowell B, Stenman U-H. Purification and characterisation of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 1995:41: 1567-73
24. Espana F, Sanchez CJ. Vera CD, Estelles A. Gilabert J. A quantitative ELISA for the measurement of complexes of prostate-specific antigen with protein C inhibitor when using a purified standard. J Lab Clin Med 1993; 122: 711-19
25. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-23
26. van Straalen J. Bossens M, de Rejke T, Sanders G. Biological half-life of prostate specific antigen after radical prostatectomy. Eur J Clin Chem Clin Biochem 1994; 32: 53-5
27. Björk T, Bjartell A, Abrahamsson PA, Hulkko S. di Sant'Agnese A, Lilja H. Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology 1994; 43: 427-34
28. Sottrup-Jensen L. Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 1989; 264: 11539-42
29. Bjartell A. Björk G. Matikainen M-T. Abrahamsson P, di Sant'Agnese A, Lilja H. Production of alpha1-antichymotrypsin by PSA-containing cells of the human prostatic epithelium. Urology 1994; 42: 502-10
30. Chen Z, Chen H. Stamey T. Prostate specific antigen (PSA) in benign prostatic hyperplasia (BPH) tissue is different from PSA in prostate cancer (PCa) tissue. J Urol 1996; 155: 696A (Abstr)
31. Stamey TA. Kabalin JN. Ferrari M, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients. J Urol 1989: 141: 1088-90
32. Guess HA, Heyse JF, Gormley GJ. The effect of flnasteride on prostate-specific antigen in men with benign prostatic hyperplasia. Prostate 1993; 22: 31-7
33. Glenski WJ, KLee GG, Bergstralh EJ, Oesterling JE. Prostatespecific antigen: establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. Prostate 1992: 21: 99-110
34. Prestigiacomo AF, Stamey TA. Physiological variation of serum prostate specific antigen in the 4.0-10.0 ng/mL range in male volunteers. J Urol 1996; 155: 1977-80
35. Simak R, Madersbacher S, Zhang ZF, Maier U. The impact of ejaculation on serum prostate specific antigen. J Urol 1993; 150: 895-7
36. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ. Oesterling JE. Ejaculation increases the serum prostatespecific antigen concentration. Urology 1996; 47: 511-16
37. Leinonen J, Lövgren T, Vornanen T, Stenman U-H. Doublelabel time-resolved immunofluorometric assay of prostatespecific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem 1993; 39: 2098-103
38. Paus E, Fosså S, Nilsson O, Eri M. The ratio of free to total PS A may be influenced by handling of serum samples. Anticancer Res 1995; 15: 2402 (Abstr)
39. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostatespecific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 2031-40
40. Carter HB, Pearson JD, Metter EJ et al Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20
41. Sakr W, Grignon D, Haas G, Heilbrun J, Crissman J, Pones J. Pathology of prostate cancer and premalignant lesions in African-American and Caucasian men: an epidemiologic and morphologic study. In Cockett A, Aso Y, Chatelain C et al, eds. Proceedings of the Third International Consultation on Benign Prostatic Hyperplasia. Scientific Communication Int, 1996: 389-400
42. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
43. Gann P, Hennekens C. Stampfer M. A prospective evalu-ation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94
44. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J. Pauker SG, Detsky AS. Screening for prostate cancer. A decision analytic view. JAMA 1994; 272: 773-80
45. Johansson J-E, Adami H-O, Andersson S, Bergström R, Holmberg L, Krusemo U. High 10-year survival rate in patients with early untreated prostate cancer. JAMA 1992; 267: 2191-6
46. Dugan JA. Bostwick DG. Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996; 275: 288-94
47. Albertsen P, Fryback D, Storer B, Kolon T, Fine J. Longterm survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-31
48. Franks L. Latent carcinoma of the prostate. J Path Bact 1954; 68: 603-16
49. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 1989; 141: 1091-4
50. Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992; 52: 3323-8
51. Christensson A, Björk T, Nilsson 0 et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-5
52. Catalona WJ, Smith DS, Wolfert RL et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20
53. Auvinen A, Tammela T, Stenman U-H et al. Screening for prostate cancer using prostate specific antigen. A randomised, population based study in Finland. Er J Cancer 1996; 74: 568-72